Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

One small STEP, one giant leap: Semaglutide in the obese phenotype of heart failure with preserved ejection fraction.

Med (New York, N.Y.) - 8 Mar 2024

Sato Ryosuke, von Haehling Stephan

Abstract excerpt

While bodyweight reduction should be a primary intervention target in obese heart failure with preserved ejection fraction (HFpEF) patients, no pharmacological treatments have shown evidence. The STEP HFpEF trial1 showed that semaglutide significantly improved various aspects of heart failure-related clinical outcomes in obese HFpEF patients, along with remarkable weight loss.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Heart Failure
Share to Obesity
Share to Phenotype

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Stroke Volume

Source

Identifiers

PMID: 38460497
DOI: 10.1016/j.medj.2023.12.012

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

One small STEP, one giant leap: Semaglutide in the obese phenotype of heart failure with preserved ejection fraction.PMID 38460497Read ↗

Design and Baseline Characteristics of STEP-HFpEF Program Evaluating Semaglutide in Patients With Obesity HFpEF Phenotype.Semantic proximity Read ↗

Semaglutide for the Silent Phenotype: A Translational Signal in Obesity-Driven HFpEF.Semantic proximity Read ↗

Precision obesity medicine: A phenotype-guided framework for pharmacologic therapy across the lifespan.Semantic proximity Read ↗

Obesity/cardiometabolic phenotype of heart failure with preserved ejection fraction: mechanisms to recent trials.Semantic proximity Read ↗

Obese phenotype and natriuretic peptides in patients with heart failure with preserved ejection fraction.Semantic proximity Read ↗

Does Characterization of Phenotypic Heterogeneity Provide Mechanistic Insights or Influence the Response to Treatment? Experience in Positive and Neutral Trials in Patients With Heart Failure and a Preserved Ejection Fraction.Semantic proximity Read ↗

Salt-inducible kinase inhibition promotes weight loss and improves the diastolic function of obesity-related heart failure with preserved ejection fraction in miceSemantic proximity Read ↗

Evidence Supporting the Existence of a Distinct Obese Phenotype of Heart Failure With Preserved Ejection Fraction.Semantic proximity Read ↗

Role of Glucagon-like Peptide-1 Receptor Agonists (GLP-1RAs) in Patients with Chronic Heart FailureSemantic proximity Read ↗

Multidisciplinary Lifestyle Interventions In The Management of Resistant HypertensionSemantic proximity Read ↗

Implications of obesity on clinical outcomes in acute decompensated heart failure across the left ventricular ejection fraction spectrum and right ventricular dysfunction.Semantic proximity Read ↗

Sodium-glucose co-transporter 2 Inhibitors Act Independently of <i>SGLT2</i> to Confer Benefit for Heart Failure with Reduced Ejection Fraction in MiceSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.